Skip to main content

Table 2 MTX resistance-related variables in precursor B and T cell ALL

From: Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia

 

Precursor B cell ALL

T cell ALL

 

N

Median (range)

N

Median (range)

P value

TSIA cont.

85

0.058 (0.01–0.76)

30

0.062 (0.01–0.22)

0.595

TSIA short

87

0.37 (0.16–12.97)

30

1.44 (0.16–40.0)

<0.001

MTX-Glu1–6

97

1210 (120–4838)

31

630 (314–1943)

<0.001

MTX-Glu4–6

83

856 (80–3190)

25

260 (0–843)

<0.001

DHFR mRNA

37

3.86 (0.27–55.06)

17

12.42 (1.48–34.11)

<0.001

TS mRNA

37

2.64 (0.24–23.04)

18

10.26 (1.64–25.04)

<0.001

FPGS mRNA

32

6.26 (1.12–39.64)

20

2.39 (0.52–17.20)

0.008

FPGH mRNA

27

2.12 (0.16–18.00)

16

4.83 (0.18–27.65)

0.196

RFC mRNA

35

0.89 (0.24–6.90)

20

0.79 (0.23–4.79)

0.668

FPGS activity

57

1.01 (0.03–11.33)

16

0.18 (0.02–1.57)

<0.001

  1. P value is determined by the Mann–Whitney U test; TSIA continuous (TSIA cont.) and short-term exposure (TSIA short) are expressed as the concentration of MTX (in μM) necessary to inhibit 50 % of the TS activity (TSI50) compared to the controls incubated without MTX (in triplicate); the concentration of MTX polyglutamates (MTX-Glu1–6 and MTX-Glu4–6) are expressed as pmol MTX-Glun/109 cells; mRNA expression of folate enzymes is expressed as ratio normalized to β-actin; FPGS activity is expressed as pmol MTX-Glu2 formed/h/106 cells
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us